Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 22,924	$ (896)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Deferred income taxes	4,212	0
Depreciation expense	196	140
Amortization of intangible assets	712	104
Stock-based compensation	4,193	2,869
Change in fair value of contingent consideration	426	159
Gain on sale of diclofenac-misoprostol	0	(1,750)
Interest expense	27	0
Changes in operating assets and liabilities:
Increase in accounts receivable	(42,548)	(259)
(Increase) decrease in inventories	(276)	7,281
Decrease (increase) in prepaid expenses and other current assets	3,252	(183)
(Increase) decrease in other assets	(27)	49
Increase in accounts payable	4,311	6,438
Decrease in deferred revenue	0	(6,000)
Decrease in accrued expenses and other liabilities	(9,838)	(4,844)
Net cash (used in) provided by operating activities	(12,436)	3,108
Cash flows from investing activities:
Purchase of property and equipment	(676)	(804)
Purchase of short term investments	0	(62,000)
Maturities of short term investments	0	62,000
Payment for business acquisition	0	(4,850)
Proceeds from sale of diclofenac-misoprostol	0	1,750
Net cash used in investing activities	(676)	(3,904)
Cash flows from financing activities:
Proceeds from common stock option exercise	2,137	0
Payment of debt financing costs	(482)	0
Repurchases of common stock	(13,653)	0
Net cash used in financing activities	(11,998)	0
Net decrease in cash	(25,110)	(796)
Cash and cash equivalents at beginning of period	52,820	79,083
Cash and cash equivalents at end of period	27,710	78,287
Non-cash financing activities
Contingent consideration - business acquisition	$ 0	$ 6,370